TransCode Therapeutics Regains Nasdaq Compliance For Minimum Bid Price, Shareholders' Equity, And Shareholder Approval Rule

Benzinga · 01/07 13:02

Shares To Remain Listed With Discretionary Panel Monitoring Until Dec. 2025